Arsanis Competitors

Longboard Pharmaceuticals (NASDAQ:LBPH) and Arsanis (NASDAQ:ASNS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares Longboard Pharmaceuticals and Arsanis' top-line revenue, earnings per share and valuation.

Longboard Pharmaceuticals has higher earnings, but lower revenue than Arsanis.

Insider and Institutional Ownership

77.4% of Arsanis shares are owned by institutional investors. 50.9% of Arsanis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Longboard Pharmaceuticals and Arsanis' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Longboard Pharmaceuticals and Arsanis, as provided by MarketBeat.com.

Longboard Pharmaceuticals presently has a consensus target price of $32.75, suggesting a potential upside of 223.30%. Given Longboard Pharmaceuticals' higher probable upside, analysts plainly believe Longboard Pharmaceuticals is more favorable than Arsanis.

Summary

Longboard Pharmaceuticals beats Arsanis on 4 of the 7 factors compared between the two stocks.

Arsanis (NASDAQ:ASNS) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Earnings and Valuation

This table compares Arsanis and Gain Therapeutics' gross revenue, earnings per share and valuation.

Gain Therapeutics has lower revenue, but higher earnings than Arsanis.

Institutional & Insider Ownership

77.4% of Arsanis shares are owned by institutional investors. 50.9% of Arsanis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Arsanis and Gain Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for Arsanis and Gain Therapeutics, as reported by MarketBeat.com.

Gain Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 114.75%. Given Gain Therapeutics' higher possible upside, analysts clearly believe Gain Therapeutics is more favorable than Arsanis.

Summary

Gain Therapeutics beats Arsanis on 4 of the 7 factors compared between the two stocks.

Arsanis (NASDAQ:ASNS) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Profitability

This table compares Arsanis and Annovis Bio's net margins, return on equity and return on assets.

Institutional & Insider Ownership

77.4% of Arsanis shares are owned by institutional investors. 50.9% of Arsanis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Arsanis and Annovis Bio's gross revenue, earnings per share and valuation.

Annovis Bio has lower revenue, but higher earnings than Arsanis.

Analyst Ratings

This is a breakdown of current ratings and price targets for Arsanis and Annovis Bio, as reported by MarketBeat.com.

Summary

Arsanis beats Annovis Bio on 3 of the 5 factors compared between the two stocks.

Evaxion Biotech A/S (NASDAQ:EVAX) and Arsanis (NASDAQ:ASNS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Evaxion Biotech A/S and Arsanis, as reported by MarketBeat.

Evaxion Biotech A/S currently has a consensus target price of $18.00, suggesting a potential upside of 162.77%. Given Evaxion Biotech A/S's higher possible upside, equities research analysts plainly believe Evaxion Biotech A/S is more favorable than Arsanis.

Profitability

This table compares Evaxion Biotech A/S and Arsanis' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Evaxion Biotech A/S and Arsanis' gross revenue, earnings per share (EPS) and valuation.

Evaxion Biotech A/S has higher earnings, but lower revenue than Arsanis.

Institutional & Insider Ownership

77.4% of Arsanis shares are held by institutional investors. 50.9% of Arsanis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Evaxion Biotech A/S beats Arsanis on 4 of the 7 factors compared between the two stocks.

Arsanis (NASDAQ:ASNS) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Institutional and Insider Ownership

77.4% of Arsanis shares are held by institutional investors. 50.9% of Arsanis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Arsanis and Longeveron, as provided by MarketBeat.com.

Profitability

This table compares Arsanis and Longeveron's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Arsanis and Longeveron's revenue, earnings per share (EPS) and valuation.

Longeveron has lower revenue, but higher earnings than Arsanis.

Summary

Arsanis beats Longeveron on 3 of the 5 factors compared between the two stocks.

Arsanis (NASDAQ:ASNS) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Arsanis and Chemomab Therapeutics, as provided by MarketBeat.

Earnings & Valuation

This table compares Arsanis and Chemomab Therapeutics' revenue, earnings per share (EPS) and valuation.

Chemomab Therapeutics has lower revenue, but higher earnings than Arsanis.

Institutional & Insider Ownership

77.4% of Arsanis shares are held by institutional investors. 50.9% of Arsanis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Arsanis and Chemomab Therapeutics' net margins, return on equity and return on assets.

Summary

Arsanis beats Chemomab Therapeutics on 3 of the 5 factors compared between the two stocks.